» Articles » PMID: 28946762

Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States

Overview
Journal Am J Psychiatry
Specialty Psychiatry
Date 2017 Sep 27
PMID 28946762
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The authors sought to determine whether cannabis use is associated with a change in the risk of incident nonmedical prescription opioid use and opioid use disorder at 3-year follow-up.

Method: The authors used logistic regression models to assess prospective associations between cannabis use at wave 1 (2001-2002) and nonmedical prescription opioid use and prescription opioid use disorder at wave 2 (2004-2005) of the National Epidemiologic Survey on Alcohol and Related Conditions. Corresponding analyses were performed among adults with moderate or more severe pain and with nonmedical opioid use at wave 1. Cannabis and prescription opioid use were measured with a structured interview (the Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV version). Other covariates included age, sex, race/ethnicity, anxiety or mood disorders, family history of drug, alcohol, and behavioral problems, and, in opioid use disorder analyses, nonmedical opioid use.

Results: In logistic regression models, cannabis use at wave 1 was associated with increased incident nonmedical prescription opioid use (odds ratio=5.78, 95% CI=4.23-7.90) and opioid use disorder (odds ratio=7.76, 95% CI=4.95-12.16) at wave 2. These associations remained significant after adjustment for background characteristics (nonmedical opioid use: adjusted odds ratio=2.62, 95% CI=1.86-3.69; opioid use disorder: adjusted odds ratio=2.18, 95% CI=1.14-4.14). Among adults with pain at wave 1, cannabis use was also associated with increased incident nonmedical opioid use (adjusted odds ratio=2.99, 95% CI=1.63-5.47) at wave 2; it was also associated with increased incident prescription opioid use disorder, although the association fell short of significance (adjusted odds ratio=2.14, 95% CI=0.95-4.83). Among adults with nonmedical opioid use at wave 1, cannabis use was also associated with an increase in nonmedical opioid use (adjusted odds ratio=3.13, 95% CI=1.19-8.23).

Conclusions: Cannabis use appears to increase rather than decrease the risk of developing nonmedical prescription opioid use and opioid use disorder.

Citing Articles

Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning.

Jayawardhana J, Hou J, Freeman P, Talbert J JAMA Psychiatry. 2024; 82(3):228-236.

PMID: 39714863 PMC: 11883495. DOI: 10.1001/jamapsychiatry.2024.4145.


Exploring Algorithmic Explainability: Generating Explainable AI Insights for Personalized Clinical Decision Support Focused on Cannabis Intoxication in Young Adults.

Zhang T, Chung T, Dey A, Bae S 2024 Int Conf Act Behav Comput (2024). 2024; 2024.

PMID: 39600343 PMC: 11586775. DOI: 10.1109/abc61795.2024.10652070.


The role of cannabis on total hip and knee surgeries outcomes: a systematic review and meta-analysis.

Hoveidaei A, Pouramini A, Mousavi-Nasab M, Taghavi P, Miri L, Saggar R Int Orthop. 2024; 49(2):343-355.

PMID: 39562357 DOI: 10.1007/s00264-024-06359-2.


Prevalence and Effect of Cannabinoids in Pain Management for Hand Pathologies.

Sleiman M, Straszewski A, Stepan J, Conti Mica M Hand (N Y). 2024; :15589447241284275.

PMID: 39392237 PMC: 11559846. DOI: 10.1177/15589447241284275.


Preoperative Cannabis Use Did Not Increase Opioid Utilization After Primary Total Knee Arthroplasty in a Propensity Score-Matched Model.

Puri S, Ong C, Chiu Y, Lebowitz J, Sideris A, Gonzalez Della Valle A HSS J. 2024; 20(2):268-273.

PMID: 39281986 PMC: 11393616. DOI: 10.1177/15563316221151158.


References
1.
Grant B, Dawson D, Stinson F, Chou P, Kay W, Pickering R . The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. Drug Alcohol Depend. 2003; 71(1):7-16. DOI: 10.1016/s0376-8716(03)00070-x. View

2.
Blanco C, Alderson D, Ogburn E, Grant B, Nunes E, Hatzenbuehler M . Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend. 2007; 90(2-3):252-60. DOI: 10.1016/j.drugalcdep.2007.04.005. View

3.
Abrams D, Couey P, Shade S, Kelly M, Benowitz N . Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011; 90(6):844-51. DOI: 10.1038/clpt.2011.188. View

4.
Tanda G, Pontieri F, Di Chiara G . Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997; 276(5321):2048-50. DOI: 10.1126/science.276.5321.2048. View

5.
Powell D, Pacula R, Jacobson M . Do medical marijuana laws reduce addictions and deaths related to pain killers?. J Health Econ. 2018; 58:29-42. PMC: 7867411. DOI: 10.1016/j.jhealeco.2017.12.007. View